ストックスクリーナーアプリを入手
33.36
3.31%
1.07
プレマーケット:
32.30
-1.06
-3.18%
Spyre Therapeutics Inc (SYRE) 最新ニュース
Trend Review: Is Spyre Therapeutics Incs ROIC above industry averagePrice Action & Weekly Top Performers Watchlists - baoquankhu1.vn
Is Spyre Therapeutics Incs ROIC above industry averageJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre’s new commercial chief granted 108K stock options at $34.09 - Stock Titan
Insider Buy: Can SYFPRA maintain sales growthAnalyst Upgrade & AI Forecast Swing Trade Picks - baoquankhu1.vn
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Biotech Gem With 65% Upside Potential - DirectorsTalk Interviews
Bull Run: Can Spyre Therapeutics Inc lead its sector in growth2025 Geopolitical Influence & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Aug Final Week: Is FORL a defensive stockChart Signals & Accurate Trade Setup Notifications - baoquankhu1.vn
Big Picture: How does Spyre Therapeutics Inc score in quality rankings2025 Price Action Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development - MSN
Wall Street bullish on Spyre Therapeutics, Inc. (SYRE) with strong buy rating - MSN
Weekly Trades: Is FNGSs growth already priced inTrend Reversal & Growth Focused Entry Point Reports - baoquankhu1.vn
Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance - Yahoo Finance
SYRE: BTIG Reiterates Buy Rating with $70 Price Target | SYRE St - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research - MarketBeat
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating - Insider Monkey
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% HigherWhat's Next? - MarketBeat
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments By Investing.com - Investing.com Nigeria
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072 - MSN
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments - Investing.com
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership - TipRanks
Quarterly Risk: Is Spyre Therapeutics Inc a top pick in the sectorMarket Activity Summary & High Conviction Trade Alerts - baoquankhu1.vn
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts - TradingView — Track All Markets
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - The Manila Times
Spyre Therapeutics IncSkyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule - TradingView
Six drug trials target colitis and arthritis, with first patient data in 2026 - Stock Titan
Spyre Therapeutics' CEO Sells 15,000 Shares - The Motley Fool
What technical charts say about OXYWS stockJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Sentiment Recap: Is Spyre Therapeutics Inc. stock cheap at current valuation2025 Pullback Review & Smart Investment Allocation Insights - Улправда
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Innovative Biotech with 86.51% Upside Potential - DirectorsTalk Interviews
Why Spyre Therapeutics Inc. stock is popular among millennials2025 Geopolitical Influence & Technical Entry and Exit Tips - Улправда
Why Spyre Therapeutics Inc. stock remains resilient2025 Market Overview & Verified Entry Point Detection - Улправда
Is Spyre Therapeutics Inc. stock a contrarian buy2025 Pullback Review & Entry and Exit Point Strategies - Улправда
Is Spyre Therapeutics Inc. stock positioned for digital transformationPortfolio Profit Report & Capital Efficient Trading Techniques - Улправда
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Brokerages - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aeglea BioTherapeutics Announces Grants of Inducement Awards - Quantisnow
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock - MarketBeat
Turtle Cameron, CEO of Spyre Therapeutics, sells $460k in shares - Investing.com Canada
Institution Moves: Is Spyre Therapeutics Inc stock a contrarian buy2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next - TechStock²
Spyre Therapeutics stock slid 6.6% into the weekend — here’s what matters before Monday’s open - TechStock²
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5% – Time to Sell? - Defense World
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus - TechStock²
Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next - ts2.tech
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5%Time to Sell? - MarketBeat
Spyre Therapeutics (SYRE) Sees Significant Decline in Stock Value - GuruFocus
Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha
CapEx per share of Spyre Therapeutics, Inc – SWB:3920 - TradingView — Track All Markets
Spyre Therapeutics Slides Despite Bullish Long-Term Hopes - TipRanks
Street Watch: Is Spyre Therapeutics Inc stock a contrarian buyQuarterly Market Summary & Daily Entry Point Trade Alerts - moha.gov.vn
Trend Recap: What makes Spyre Therapeutics Inc. stock attractive to growth fundsJuly 2025 Earnings & Detailed Earnings Play Alerts - Улправда
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):